<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03247920</url>
  </required_header>
  <id_info>
    <org_study_id>RAIN</org_study_id>
    <nct_id>NCT03247920</nct_id>
  </id_info>
  <brief_title>Reduction of Intravenous Antibiotics In Neonates</brief_title>
  <acronym>RAIN</acronym>
  <official_title>Intravenous to Oral Antibiotic Switch Therapy for Suspected Neonatal Bacterial Infections: Clinical Efficacy, Safety and Cost-effectiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Franciscus Gasthuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Franciscus Gasthuis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled open-label non-inferiority trial comparing complete intravenous
      antibiotic treatment with a short iv. course followed by oral antibiotics in neonates (0-28
      days) with probable bacterial infection.

      Primary outcome:

      - Bacterial re-infection within 28 days after finishing of antibacterial therapy.

      Secondary outcome(s):

        -  Pharmacokinetic profile of oral amoxicillin/clavulanic acid

        -  Quality of life

        -  Cost-effectiveness

        -  Alterations in gut microbiome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neonates have a high antibiotic consumption because of their susceptibility for bacterial
      infections. Since the early diagnosis of bacterial infection in neonates is difficult,
      intravenous broad-spectrum antimicrobial therapy is usually started promptly after subtle
      symptoms. The majority of neonates become asymptomatic shortly after initiation; when
      infection is probable or proven by elevated inflammatory markers and/or a positive blood
      culture, intravenous antibiotics are administered for at least 7 days.

      However, for neonates blood culture has a limited sensitivity. Therefore, the majority of
      neonates with probable infection are treated for a prolonged time with intravenous
      broad-spectrum antimicrobial therapy. In older children, intravenous antibiotics are often
      changed to oral antibiotics after cessation of symptoms and decreasing inflammatory
      parameters. This is not yet widely practised in neonates because of uncertainties in
      pharmacokinetics. Two explorative small studies from France and Italy into neonatal
      antibiotic switch therapy suggest that follow-up treatment with an oral antibiotic is
      promising; but the non-inferiority and safety was not yet properly addressed. Neonatal switch
      therapy, if proven to be safe and efficacious, would have a major impact on neonatal
      well-being, mother-to-child bonding and moreover costs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter prospective randomized controlled non-inferiority trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial re-infection within 28 days after cessation of antibiotic treatment (within 35 days after initial presentation)</measure>
    <time_frame>0-35 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>0-35 days after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of re-admission</measure>
    <time_frame>0-35 days after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total costs and cost-effectiveness</measure>
    <time_frame>0-35 days after birth</time_frame>
    <description>Cost-effectiveness of intravenous to oral switch compared to a full course of antibiotics + possible extra costs due to early antibiotic switch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At day 7 &amp; day 35 post partum</time_frame>
    <description>Quality of life will be assessed using a questionnaire on day 7 and 21 after admission, filled in by both parents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time above MIC (T&gt;MIC) of oral amoxicillin.</measure>
    <time_frame>0-7 days</time_frame>
    <description>2 blood samples after administration of antibiotic suspension at different time points will be taken.
Time above MIC (T&gt;MIC) will be defined. Target MIC is 8 mg/liter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time above MIC (T&gt;MIC) of oral clavulanic acid.</measure>
    <time_frame>0-7 days</time_frame>
    <description>2 blood samples after administration of antibiotic suspension at different time points will be taken.
Time above MIC (T&gt;MIC) will be defined. Target MIC is 8 mg/liter.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Neonatal Infection</condition>
  <condition>Neonatal SEPSIS</condition>
  <arm_group>
    <arm_group_label>Oral group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After 48 hours of intravenous antibiotics eligible neonates will switch to amoxicillin/clavulanic acid suspension for the remaining 5 days. When the oral suspension is well tolerated neonates can be discharged from hospital.
In order to investigate the pharmacokinetic profile of oral amoxicillin/clavulanic acid serum levels will be measured.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neonates will complete the full course of antibiotics of 7 days intravenously in hospital following local protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin Clavulanate</intervention_name>
    <description>Dose 75 mg/kg/day, (3dd 25 mg/kg). Concentration amoxicillin/clavulanic acid: 4:1</description>
    <arm_group_label>Oral group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>Intravenous antibiotic therapy following local protocol</description>
    <arm_group_label>Intravenous group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neonates (≥ 35+0 weeks, 0-28 days old, ≥ 2 kg)

          -  Probable bacterial infection defined as clinical symptoms and/or maternal risk factors
             and elevated inflammatory markers for which empiric broad-spectrum antibiotic
             treatment was initiated and needs to be continued for &gt; 48 hours

          -  Clinical stable

          -  Reassuring levels of inflammatory parameters 48-72 hours after initiation of therapy

          -  Toleration of oral feeding without overt vomiting

          -  Signed informed consent

        Exclusion Criteria:

          -  Proven bloodstream infection

          -  Absence of blood culture

          -  Severe localized infection (meningitis, osteomyelitis, necrotizing enterocolitis)

          -  Severe clinical sepsis (compromised circulation, need for mechanical ventilation)

          -  Continuous need for a central venous line

          -  Severe hyperbilirubinemia exceeding the exchange level

          -  Parents inability to administer medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fleur Keij, MD</last_name>
    <phone>(0)655805452</phone>
    <phone_ext>+31</phone_ext>
    <email>rainstudie@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerdien Tramper, MD, PhD</last_name>
    <email>g.tramper@franciscus.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IJsselland Ziekenhuis</name>
      <address>
        <city>Capelle Aan Den IJssel</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arianne van Driel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC-Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René Kornelisse, MD/PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Kamerbeek, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gerdien Tramper, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul den Butter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franciscus Vlietland</name>
      <address>
        <city>Schiedam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Kenter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline vd Sluijs, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.rainstudie.nl</url>
    <description>Study website (in dutch)</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Franciscus Gasthuis</investigator_affiliation>
    <investigator_full_name>Gerdien Tramper</investigator_full_name>
    <investigator_title>Principal investigator, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Antibiotic switch therapy</keyword>
  <keyword>Amoxicillin/clavulanic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

